Rigel Pharmaceuticals Company Profile (NASDAQ:RIGL)

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) posted its quarterly earnings results on Tuesday, August, 1st. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.01. Rigel Pharmaceuticals had a negative net margin of 354.14% and a negative return on equity of 105.86%. During the same quarter last year, the firm earned ($0.15) earnings per share. View Rigel Pharmaceuticals' Earnings History.

Rigel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, October, 30th 2017. View Earnings Estimates for Rigel Pharmaceuticals.

4 brokers have issued 12 month target prices for Rigel Pharmaceuticals' shares. Their forecasts range from $5.00 to $11.00. On average, they expect Rigel Pharmaceuticals' share price to reach $6.75 in the next twelve months. View Analyst Ratings for Rigel Pharmaceuticals.

Here are some recent quotes from research analysts about Rigel Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer. " (9/20/2017)
• 2. Jefferies Group LLC analysts commented, "RIGL is on track to submit an NDA for fosta in ITP in 1Q17; next major catalyst could be FDA acceptance by ~May given mixed Ph3 data & limited FDA interactions following Ph3 data. YE16 cash of ~$75M, plus net proceeds of $43M from recent offering, should be sufficient at least for next 12 months including pre-commercial activities, per RIGL. If fosta is approved in ITP, we see >50% upside to our current PT of $5." (3/8/2017)
• 3. BMO Capital Markets analysts commented, "We remain focused on fostamatinib's pending NDA submission, which we believe supports approval given clear and consistent benefit in ITP, despite one pivotal trial missing statistical significance. We believe reaching an FDA Adcom would be a positive event, as a panel of clinicians would likely recommend approval. Additionally, we believe the fostamatinib addressable patient population is larger than the 18% stable response rate, as real world use would include patients who maintain platelet counts greater than 30K/ul, according to physician feedback. We rate RIGL shares Outperform." (3/8/2017)

Some companies that are related to Rigel Pharmaceuticals include Synergy Pharmaceuticals (SGYP), Achillion Pharmaceuticals (ACHN), Adaptimmune Therapeutics PLC (ADAP), Sucampo Pharmaceuticals (SCMP), Clementia Pharmaceuticals (CMTA), Aurinia Pharmaceuticals (AUPH), Karyopharm Therapeutics (KPTI), Atara Biotherapeutics (ATRA), Progenics Pharmaceuticals (PGNX), GlycoMimetics (GLYC), Jounce Therapeutics (JNCE), NantKwest (NK), Madrigal Pharmaceuticals (MDGL), BioCryst Pharmaceuticals (BCRX), Selecta Biosciences (SELB), AVEO Pharmaceuticals (AVEO), Mersana Therapeutics (MRSN) and Urogen Pharma (URGN).

Rigel Pharmaceuticals' management team includes the folowing people:

• Raul R Rodriguez, President, Chief Executive Officer, Director
• Ryan D. Maynard, Chief Financial Officer and Executive Vice President
• Dolly A. Vance, Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary
• Eldon C. Mayer III, Executive Vice President, Chief Commercial Officer
• Anne-Marie Duliege M.D., Chief Marketing Officer
• Keith A. Katkin, Director
• Brian L. Kotzin M.D., Director
• Bradford S. Goodwin, Independent Director
• Gary A. Lyons, Independent Director
• Walter H. Moos Ph.D., Independent Director

Rigel Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.76%), Vanguard Group Inc. (4.86%), Palo Alto Investors LLC (3.10%), NEA Management Company LLC (2.65%), State Street Corp (1.76%) and Marshall Wace North America L.P. (1.62%). Company insiders that own Rigel Pharmaceuticals stock include Anne-Marie Duliege and Donald G Payan. View Institutional Ownership Trends for Rigel Pharmaceuticals.

Rigel Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Palo Alto Investors LLC, DAFNA Capital Management LLC, New York State Common Retirement Fund, California State Teachers Retirement System, Bank of New York Mellon Corp, Goldman Sachs Group Inc. and ProShare Advisors LLC. View Insider Buying and Selling for Rigel Pharmaceuticals.

Rigel Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., B. Riley Financial Inc., Paulson & CO. Inc., Northern Trust Corp, Macquarie Group Ltd., Candriam Luxembourg S.C.A., State Street Corp and State of Wisconsin Investment Board. View Insider Buying and Selling for Rigel Pharmaceuticals.

Shares of Rigel Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Rigel Pharmaceuticals stock can currently be purchased for approximately $2.37.